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Abstract
Transcriptional silencing of the p73 gene through methylation has been demonstrated in human leukemias and
lymphomas. However, the role of p73 in the malignant process remains to be explored. We show here that p73 acts as a T
cell-specific tumor suppressor in a genetically defined mouse model, and that concomitant ablation of p53 and p73
predisposes mice to an increased incidence of thymic lymphomas compared to the loss of p53 alone. Our results
demonstrate a causal role for loss of p73 in progression of T cell lymphomas to the stage of aggressive, disseminated
disease. We provide evidence that tumorigenesis in mice lacking p53 and p73 proceeds through mechanisms involving
altered patterns of gene expression, defects in early T cell development, impaired apoptosis, and the ensuing accumulation
of chromosomal aberrations. Collectively, our data imply that tumor suppressive properties of p73 are highly dependent on
cellular context, wherein p73 plays a major role in T cell development and neoplasia.
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Introduction
The p73 gene was identified as a structural p53 homologue and
a potential tumor suppressor [1,2]. However, in contrast to the
established role of p53 in cancer prevention, a similar role of p73
in oncogenesis remains to be explored. Despite the purported
ability of p73 to activate p53-responsive genes, p73-deficient cells
do not display a proliferative advantage similar to that of p53-null
cells [3,4]. The p73 gene is rarely mutated in human cancers, and
no compelling evidence exists that p73 inactivation is required for
tumor initiation or progression [5]. Apart from subsets of acute
lymphoblastic leukemia and non-Hodgkin’s lymphomas, few other
human tumor types inactivate p73 through epigenetic silencing
[6–8].
Unlike p53, the p73 gene locus gives rise to a complex pattern of
isoforms with seemingly antagonistic properties. Many of the
tumors upregulate the N-terminally truncated DNp73 isoforms,
often in conjunction with transactivation competent full-length
TAp73 [9–11]. Targeted inactivation of TAp73 in mice produces
a phenotype similar to that of p53+/2 mice in terms of incidence
and latency of tumors [12]. In contrast, Trp73 knockout mice
(which lack all p73 isoforms) exhibit multiple developmental
defects but no tumor predisposition [13]. These data imply that
TAp73 may act as a tumor suppressor, while DNp73 augments
tumor development in vivo. In support, overexpression of DNp73
promotes cellular immortalization and oncogenic transformation,
albeit with low efficiency compared to p53 dominant-negative
mutants [14]. Also, upregulation of DNp73 is associated with poor
prognosis in human cancers [5,15].
An open question is whether p73 contributes to p53-mediated
tumor suppression. One recent study showed that mice heterozy-
gous for both p53 and p73 display higher tumor burden and
metastasis compared to p53+/2 mice [16], suggesting that
mutations affecting p53 and p73 have additive effects in vivo.
However, this gene interaction appears to be tissue-specific, as in a
separate study p53+/2 and p53+/2p73+/2 mice exhibited no
differences in radiation-induced lymphomagenesis [17]. Likewise,
it was suggested that p73 loss impairs p53-dependent apoptosis in
response to DNA damage [18]. However, p73 was found to be
dispensable for p53-dependent apoptosis of T cells in vivo [3].
Moreover, the poor transforming properties of p73-deficient
MEFs were seen as a consequence of compensatory activation
rather than weakening of p53 [4]. Here, we set out to clarify this
functional p53-p73 interrelationship by analyzing spontaneous
tumorigenesis in mice deficient for both p53 and p73. Our data
imply that the tumor suppressive properties of p73 are highly
dependent on cellular context, wherein p73 plays a major p53-
dependent role in T cell development and neoplasia.
Results
Mice Deficient in p53 and p73 Are Highly Prone to T Cell
Lymphomas
It was originally discovered and reported that p73-null mice
survive to birth, but then exhibit a high rate of postnatal mortality
caused by extensive brain defects, gastrointestinal hemorrhages,
chronic infections and inflammation [13]. Therefore, animal
studies to evaluate the long-term effect of p73 deficiency on cancer
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7784development were rendered not feasible. However, contrary to the
accepted view, we found that growth retardation and the reduced
postnatal survival of p732/2 mice were mainly due to
malnutrition caused by their inability to compete with WT and
p73+/2 littermates. Identifying such p732/2 pups at an early
stage and housing them with foster lactating mothers rescued
nearly 80% of the mice to adulthood (.1.5 years, Fig. 1A). Thus
far, we generated large cohorts of mice deficient for p73 and/or
p53 and monitored them for developmental defects and tumor
predisposition. In agreement with previous report [13], p732/2
mice in our group exhibited partially penetrant congenital
hydrocephalus, and 20% of them died at an early age from
intraventricular hemorrhage (Fig. 1A). Likewise, 25% to 30% of
p53+/2p732/2 and p532/2p732/2 (DKO) mice exhibited a
shortened longevity due to inherent neurodevelopmental defects
(Fig. 1A). Importantly, however, none of the long-term surviving
p732/2 mice developed clinical signs of malignancy (Fig. 1B), in
contrast to p53+/2p732/2 and DKO mice which succumbed to
tumors at a later stage (Fig. 1B).
Mice lacking p53 are developmentally normal but tumor-prone,
sustaining high rates of thymic lymphomas and other tumors
[19,20]. Most p532/2 mice in our group also succumbed to
tumors within 2–6 months (Fig. 1C, curve I). Loss of one p73 allele
had no significant effect on overall survival in this experimental
setting (Fig. 1C, curve II), while loss of both p73 alleles shortened
the lifespan of p532/2 mice, with DKO animals exhibiting a
mean survival of 3.54+/20.9 months compared to 3.92+/21.4
months of p532/2 controls (Fig. 1C, curve III). Although the
differences in terms of survival were small, loss of even one p73
allele significantly altered the tumor phenotype of p53-null mice.
Thus, p532/2 mice developed thymic lymphomas (66%), high-
grade sarcomas (26%), B cell lymphomas (8%), as well as
occasional adenocarcinomas (4%), teratocarcinomas (4%), meso-
thelioma, and medulloblastoma (Fig. 1D and Table 1). In contrast,
thymic lymphomas accounted for 82% and 83% of tumors found
in p532/2p73+/2 and DKO mice, respectively (Fig. 1D and
Table 1), whereas B cell lymphomas, sarcomas and carcinomas
were less frequent in p532/2p73+/2 mice and even less so in
DKO animals (Table 1). The differences in tumor frequencies
between p532/2 and DKO mice were statistically significant
(p,0.00091 and 0.00055 for T cell lymphomas and solid tumors,
respectively, by Kendall’s W test). Only five of forty (12.5%) DKO
mice had various types of sarcomas, while adenocarcinomas were
not found in DKO animals by the time they were 5 months old
and other tumor types occurred (Fig. 1D and Table 1). Other, less
frequent tumor types observed in DKO mice included low grade
intestinal adenomas (5%) and malignant teratomas (7.5%), to
which 129Sv mice have a modest predisposition [21].
Loss of p73 Enhances Dissemination of Lymphoma to
Peripheral Organs
A characteristic feature of lymphomas arising in p532/2 mice
is that they remain within the thymus and only rarely spread to
other organs (Fig. 2). By contrast, many of the lymphomas arising
in p532/2p73+/2 mice and virtually all thymic tumors
developed by DKO animals acquired the capacity to infiltrate
adjacent structures and the periphery. Massive lymphatic
accumulations were observed in mediastinal lymph nodes, lungs,
and, on more rare occasions, in heart, liver, and kidneys of the
affected animals (Fig. 2). At the cellular level, lymphomas arising in
p532/2p73+/2 and DKO mice were invariably immature
CD4+CD8+ double positive cells with a significant proportion of
Figure 1. Mice deficient for p53 and p73 are highly prone to T cell lymphomas. A, B. Kaplan-Meier curves of overall (A) and tumor-free
survival (B) of p732/2, p53+/2p73+/2 and p532/2p732/2 mice. The number of mice of each genotype is indicated. C. Kaplan-Meier curves of
tumor-free survival of p532/2, p532/2p73+/2 and p532/2p732/2 mice. D. Tumor spectra in mice of the indicated genotypes.
doi:10.1371/journal.pone.0007784.g001
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Most of these tumors expressed variable amounts of CD3, some of
them showing a mixture of CD3-positive and CD3-negative T
cells (data not shown). In sum, combined loss of p53 and p73
predisposes mice to lymphoblastic T cell lymphomas with
widespread dissemination to peripheral organs.
Loss of p73 Promotes T Cell Lymphomagenesis
Independent of Age
We considered a possibility that the high frequency of
lymphomas in DKO mice as compared to p532/2 mice may
be due to a block in T cell development caused by the loss of p73
function. Alternatively, it could result from phenotypic variations
in age-related thymic involution. However, thymi of 4- to 12-
week-old p732/2 and DKO mice showed a histologically
normal architecture, with well defined cortical and medullary
areas (data not shown). Furthermore, atrophy of the thymus, as
measured by total T cell reduction, was unaffected by the absence
of p73 (Fig. S1A). In contrast, the onset of lymphoma
development was accelerated in both p532/2p73+/2 and
DKO mice (Fig. 3A). Importantly, no lymphomas arising in
p532/2p73+/2 mice displayed LOH at the p73 locus (Fig. 3B),
thus indicating that not only the complete loss of p73 but also a
reduction of its dosage suffices to promote T cell lymphomagen-
esis independent of age.
Thymic involution in p53+/2 mice occurs before appreciable
numbers of thymocytes lose the remaining p53 allele [22].
Therefore, p53 heterozygous mice acquire tumors at older age,
most often osteosarcomas and soft tissue sarcomas. As shown in
Fig. 1B, the presence of one p53 allele alleviated the effects of p73
deficiencyontumorformation.However,whilethecontrol p53+/2
mice succumbed mainly to high-grade sarcomas, thymic lympho-
mas were the major tumor type seen in p53+/2p732/2 mice (Fig.
S1B, C).
Inactivation of p73 Causes Defects in T Cell Development
T cell development is characterized by the progression through
several phenotypically distinct stages, defined as double negative
(DN), double positive (DP), and single positive (SP), based on the
expression of CD4 and CD8 markers. The DN thymocyte subset is
further subdivided into four stages (DN1-4) by differential
expression of CD25 and CD44 [23]. To determine whether p73
loss affects T cell development, lymphoid organs (bone marrow,
thymi, spleens) of p732/2 and DKO mice were characterized by
flow cytometry and PCR.
The analysis revealed that p73 is expressed throughout T cell
development (Fig. 4A). The frequency of primitive lymphoid
progenitors (LSK) in bone marrow and early T lineage progenitors
(ETP) in thymi of p732/2 and DKO mice was normal (Fig. 4B).
The proportions of DP, CD4-SP and CD8-SP thymic subsets were
also comparable with those of controls (Fig. 4C). However, the
total number of thymocytes in p732/2 mice was only 70% that
of wild-type littermates (Fig. 4D). Deletion of p73 caused a partial
arrest at the DN2/DN3 stage and reduced the numbers of DN4
pro-T cells (Fig. 4E, F). DN2 and DN3 thymocytes that escaped
this partial developmental arrest retained the ability to generate
DN4 cells and undergo further differentiation (Fig. 4C). However,
in isolated cases spleens of p732/2 mice were devoid of T cells
(data not shown). In view that the generation of double strand
breaks during V(D)J recombination poses a risk for genomic
instability in DN2/DN3 and DP stage thymocytes and accumu-
lation of mutations [24], we surmised that the DNA damage
response and apoptosis might be disrupted upon combined
inactivation of p53 and p73. As reported [3], thymocytes of
p732/2 mice displayed only slightly reduced levels of apoptosis
compared to WT controls, but it was lessened by the deletion of
p53 (Fig. 4G). The developmental arrest imposed by p73
deficiency was also rescued by the deletion of p53 (Fig. 4E, F),
restoring thymic cellularity to WT control levels (Fig. 4D).
Table 1. Tumor spectrum of p532/2 mice with zero, one, or two p73 alleles.
Genotypes
Tumor types p532/2 (n=55) p532/2p73+/2 (n=57) p532/2p732/2 (n=42)
T cell lymphoma 33 (66%) 42 (82%) 33 (83%)
B cell lymphoma 4 (8%) 3 (6%) 1 (2.5%)
NOS lymphoma
a 3 (6%) 2 (4%) 1 (2.5%)
Angiosarcoma 11 (22%) 6 (12%) 4 (10%)
Fibrosarcoma 1 (2%) 1 (2%) 1 (2.5%)
Osteosarcoma 1 (2%) – –
Carcinosarcoma – 1 (2%) –
Stromal sarcoma – 1 (2%) –
Adenoma – 1 (2%) 2 (5%)
Adenocarcinoma 2 (4%) 2 (4%) –
Medulloblastoma 1 (2%) – –
Teratocarcinoma 2 (4%) 1 (2%) 3 (7.5%)
Inflammation 1 2 –
Cause not determined 4 4 2
Number of tumors 56 57 44
Tumors per mouse 1.12 1.12 1.1
The percentage of mice with tumors and the mean number of tumors per mouse are shown.
aNOS, not otherwise specified.
doi:10.1371/journal.pone.0007784.t001
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takes place correctly in thymocytes of p73-deficient mice, the
expression of the genes involved in early cell-fate decisions and
differentiationprocesses wasexamined byquantitativeRT-PCR.In
these experiments, mRNA levels of Bcl11b, Notch1, Notch3 and
pre-TCR components (pTa, CD3d, CD3e) in DN thymocytes of
p732/2 mice were markedly reduced compared with those of WT
control mice (Fig. 5A), and this expression pattern was maintained
until the DP stage (Fig. S2A-C). In contrast, p53 mRNA levels were
increased twofold in p732/2 DN cells (Fig. 5A). Likewise, p73-
deficient thymocytes contained altered mRNA levels of LFA-1
(integrin beta 2) and chemokine receptors CCR4, CCR7, CCR8,
CCR9 and CXCR5 (Fig. 5B), which have been implicated in
lymphocyte migration and dissemination [25]. Expression levels of
pTa, CD3e, CCR4, CCR7, CCR8, CCR9 and CXCR3 genes
werealsolowerinDKOcomparedtop532/2cells(Fig.5B,Cand
Fig. S2A-C). Similarities between p532/2 and DKO DP
thymocytes included conspicuously low mRNA levels of Notch1-3
and chemokine receptors CCR2, CCR4, CCR7, CCR8, CXCR3,
CXCR5, and CXCR6 (Fig. 5B). Thus, loss of p73 synergizes with
p53 loss-of-function in altering the developmental and/or migra-
tory properties of immature T cells.
Aneuploidy and Clonal Translocations Contribute to the
Development of p73-Deficient Lymphomas
At the genomic level, rearrangements involving TCRb and
TCRc gene loci were detected in premalignant thymocytes of all
genotypes (Fig. 6A), and in lymphomas derived from p532/2,
p532/2p73+/2 and DKO mice (Fig. 6B). In contrast,
interchromosomal translocations between TCRc and TCRb loci
that have been used routinely as predictors for large-scale
translocations in mouse thymocytes [26,27], were not present in
cells of either genotype (data not shown). Evidence for aberrant
V(D)J rearrangements in 73-deficient thymocytes was obtained by
assaying for internal deletion at the Bcl11b and Notch1 loci, which
both contain cryptic recombination signal sequences (RSS) that
are accessible to Rag, and are frequently mutated in T cell
lymphomas [28–30]. Deletions at the Bcl11b gene locus were
Figure 2. Loss of p73 enhances dissemination of lymphoma to peripheral organs. Hematoxylin and eosin staining of tissues from tumor-
bearing p532/2p732/2 mice showing lymphatic accumulation in lungs (A, B), liver (D), kidney (E), and heart (F). Lung section of a lymphoma-
bearing p532/2 mouse is shown for comparison (C). Magnification 4X. The table lists the numbers of thymic lymphomas from mice with the
indicated genotypes that either exhibited or lacked clear indications of invasion of peripheral organs by lymphoma.
doi:10.1371/journal.pone.0007784.g002
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and in lymphomas derived from p532/2, p532/2p73+/2 and
DKO mice (Fig. 6B). On the other hand, deletions at the Notch1
locus were found in the respective lymphomas but not in
premalignant cells (Fig. 6A, B). The frequency of Bcl11b gene
rearrangements in DKO mice was estimated to be 2 to 5-fold
higher than that in the respective p532/2 controls (Fig. 6C).
PCR of serial dilutions showed that rearrangement of the Bcl11b
gene could be reliably detected in 300 ng of thymocyte DNA
derived from premalignant p532/2 mice and 150 ng DNA from
DKO mice (data not shown). Considering that this amount of
thymocyte DNA corresponds to ,5610
4 and 2.5610
4 cell
equivalents, respectively (Sakata et al., 2004), and the normal
thymus is composed of ,5610
7 cells (see Fig. 4D), our results
suggest the existence of at least 10
3 thymocytes with internal
deletions in the Bcl11b gene in thymi of premalignant p532/2
mice and twice that number in thymi of DKO mice.
To examine chromosomal alterations associated with p53 and
p73 deficiency in more detail, array-based comparative genomic
hybridization (CGH) assays were performed on five primary
tumors of each p73 genotype. The analysis revealed that p532/
2p73+/2 and DKO lymphomas resembled p53-null tumors in
terms of extensive numerical chromosomal aberrations. Whole
chromosome gains of 4, 9, 11, 14, and 15 were common in all
types of lymphomas, indicating that tumor development in a p53-
null background favors the duplication of these chromosomes (Fig.
S3). Distinct karyotypic events were also evident, as gains of
chromosome 1 were more frequent in p73-deficient lymphomas
(Fig. S3). Spectral karyotyping (SKY) of cell lines established from
p532/2p73+/2 and DKO lymphomas revealed a modal
chromosome number of 46-52 accompanied by several types of
translocations, including t(8; 11), t(1; 10), t(13; 16), and t(16;17)
(Fig. S4). Based on these data, we conclude that tumorigenesis in
p532/2p73+/2 and DKO mice proceeds through mechanisms
involving chromosome gains, losses, and clonal translocations. The
contribution of numerical chromosomal changes is more than that
of chromosomal translocations.
Discussion
We show here that p73 acts as a T cell-specific tumor
suppressor in a genetically defined mouse model, and that
concomitant ablation of p53 and p73 predisposes mice to an
increased incidence of thymic tumors compared to the loss of p53
alone. Our results demonstrate a causal role for loss of p73 in
progression of T cell lymphomas to the stage of aggressive,
disseminated disease. We provide evidence that tumorigenesis in
mice lacking p53 and p73 proceeds through mechanisms
involving altered patterns of gene expression, defects in early T
cell development at the immature DN2-DN4 stage, impaired
apoptosis, and the ensuing accumulation of chromosomal
aberrations, i.e. chromosome gains, losses, and clonal transloca-
tions. We further demonstrate that p73 loss alone cannot initiate
tumorigenesis but it can cooperate with an initiating lesion, such
as p53 loss-of-function, to make a premalignant cell tumorigenic
and proliferatively aggressive. Based on the fact that B cell
lymphomas, carcinomas and sarcomas occurred infrequently in
p532/2p73+/2 mice and even less so in p532/2p732/2
(DKO) animals, our data imply that tumor suppressive properties
of p73 are highly dependent on cellular context, wherein p73
plays a major p53-dependent role in T cell development and
neoplasia.
There are two current concepts of the cellular mechanisms
responsible for the induction and maintenance of T cell
lymphomas. One holds that p53 participates in a checkpoint
response that eliminates DN thymocytes that do not display proper
pre-TCR signaling. Cells that fail to express the pre-TCR exhibit
developmental arrest at the DN3 stage, accompanied by massive
apoptosis [31–34]. Ablation of p53 function can restore the
survival of pre-TCR-deficient thymocytes, but at later time points
these cells consistently give rise to lymphomas [32,34,35]. Another
model holds that any genetic alteration leading to an early
lymphocyte block and prolonged expression of Rag endonucleases
can act as a procarcinogenic event, particularly in the p53 null
setting [36,37]. We present several lines of evidence to support a
model in which disease acceleration as a direct or indirect
consequence of p73 inactivation is caused by the alteration of
expression patterns of genes involved in early cell-fate decisions,
most notably pTa, CD3e, Bcl11b, and Notch1. Accumulating
evidence has highlighted the importance of these genes in the
regulation of differentiation of lymphoid progenitor cells, the pre-
TCR checkpoint and T cell-specific gene expression [28,38,39].
As previously reported [3], p732/2 mice produce a normal
repertoire of mature T cells. However, we find that from a
mechanistic perspective p73 deficiency perturbs early T cell
development and thereby increases the number of T cell
progenitors available for secondary mutations. While only a small
percentage of such cells progress beyond the DN stage due to
persistent p53-mediated cell cycle arrest and apoptosis, the
deletion of p53 rescues this defect, but it comes at the expense
of increased lymphomagenesis. Furthermore, p73-deficient thy-
mocytes exhibit altered mRNA levels of chemokine receptors such
as CCR4, CCR7, CCR8, CCR9, and CXCR3, which have been
implicated in governing lymphocyte migration and dissemination
[25].
Our findings implicate Rag activity as an important contribut-
ing factor affecting lymphoma development in a p73-null
background, while the loss of apoptosis through p53- and p73-
deficiency allows accumulation of such genetic alterations. First,
Figure 3. Loss of p73 promotes T cell lymphomagenesis
independent of age. A. The dynamics of T cell lymphoma
development in mice of the indicated genotypes. B. LOH analysis at
the p73 locus by genomic PCR of tumor tissues derived from p532/2,
p53+/2p732/2, and p532/2p732/2 (DKO) mice. Tumor numbers are
indicated.
doi:10.1371/journal.pone.0007784.g003
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normally expresses Rag. Second, Rag-mediated internal deletions
in the Bcl11b gene locus were detected in premalignant DKO
thymocytes. We find that the frequency of Bcl11b gene deletions is
twofold higher in premalignant DKO cells as compared with p53-
null controls. Third, Rag-mediated internal deletions in the
Notch1 locus were detected in DKO lymphomas, suggesting
continuous Rag gene activity during the evolution of the
transformed clones. In sum, although p532/2 and DKO
lymphomas did not harbor Rag-mediated translocations of the
TCR loci, our findings support a model in which persistent Rag
expression contributes to tumorigenesis in an overall growth
arrest-deficient and apoptosis-deficient p532/2p732/2 null
background. This model is consistent with previous reports that
linked lymphomagenesis with Rag-mediated genomic alterations
[28,36,37].
Figure 4. Inactivation of p73 causes defects in T cell development. A. Semi-quantitative RT-PCR analysis of p73 mRNA levels in sorted bone
marrow Lin-Sca1+c-Kit+ (LSK) cells, thymic CD4/CD8 double negative (DN), CD4/CD8 double positive (DP), CD4-SP and CD8-SP cells from WT mice.
HPRT is a control for equal input. p732/2 thymocytes are shown for control. B. The frequency of LSK lymphoid progenitors in bone marrow and
early T lineage progenitors (ETP) in thymi of mice of the indicated genotypes. ETP cells represent a c-Kit-positive subset of the DN1 (CD44+CD25-)
population. The error bars represent the standard error obtained from six experiments. C. Relative numbers of DP, CD4-SP and CD8-SP T cell in thymi
from 4-week old mice of the indicated genotypes. The error bars represent the standard error. D. Total cell numbers in thymi and spleens of 4 week-
old mice of the indicated genotypes. The error bars represent the standard error obtained from six experiments. E, F. Thymocytes from 4-week old
mice of the indicated genotypes were stained with antibodies to CD4, CD8, CD25 and CD44. Gating on CD4/CD8 double negative cells. Relative
numbers of DN1-4 (E) and absolute numbers of DN3/DN4 subsets (F) are indicated. The error bars represent the standard error obtained from eight
experiments. P-values for the difference between WT and p732/2 subsets are shown. G. Annexin V staining of DN and DP thymocytes from 4 week-
old mice of the indicated genotypes. The error bars represent the standard error obtained from three experiments.
doi:10.1371/journal.pone.0007784.g004
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p73-null lymphomas. We showed recently that p73 loss alters the
clinical course of Myc-driven lymphomagenesis, characterized by
a decreased tumor burden in lymphoid organs, but increased
dissemination to extranodal sites (A Nemajerova and U Moll,
submitted). Microarray analysis of p73-deficient lymphomas
revealed a number of deregulated genes that encode proteins
involved in cell adhesion and extracellular signaling. These data
provide strong evidence that p73 loss alters gene expression
patterns of various lineages. Because transcriptional silencing of
the p73 gene through methylation has been demonstrated in
human leukemias and lymphomas [6–8], it will be important to
establish if p73 plays a similar role in regulation of T cell
development and neoplasias in humans.
Materials and Methods
Ethics Statement
All research involving animals has been conducted according to
national and international guidelines with respect to husbandry,
experimentation and welfare as part of this project. All animal
studies were approved by the Institutional Animal Care and Use
Committee at Stony Brook University.
Mice and Flow Cytometry
We used previously described p73-knockout mice [13] and
p53-knockout mice [20]. All mice were housed in the maximum
isolation facility. p53+/2p73+/2 double heterozygous mice
were derived by crossing between p73+/2 and p532/2 an-
Figure 5. Loss of p73 alters the expression pattern of genes involved in T cell development. A–C. Quantitative RT-PCR analysis of genes
encoding critical factors of T cell development in DN and DP thymocytes of the indicated genotypes. Each sample was analyzed in duplicate. mRNA
expression levels were normalized to hypoxanthine-guanine phosphoribosyl transferase (HPRT) mRNA amount.
doi:10.1371/journal.pone.0007784.g005
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mice were derived from crosses between the double heterozygous
animals. p532/2p732/2 mice (DKO) were derived from
crosses between p53+/2p73+/2 double heterozygous mice or
p53+/2p73+/2 and p532/2p73+/2 mice. The genotype
of mice was verified by PCR amplification specific for the
corresponding WT and mutant alleles. Mice were observed
daily for precipitous changes in health and tumor development.
Tumors that arose were harvested and processed for histological
examination. Each tumor was fixed in formalin and sections
were stained with hematoxylin and eosin. The extent of tumor
dissemination was determined for at least 15 lymphomas of each
genotype and graded the percentage of lung tissue invaded
by lymphoma cells per 10X power field. Dissemination was
classified into4 grades: 0=nosigns of dissemination, 1=minimal
(,5 %i n v a d e dt i s s u e ) ,2=m o d e r a t e( u pt o2 0 %i n v a d e dt i s s u e ) ,
3=strong(.30% invaded tissue). Lymphoid tissue samples were
examined by flow cytometry with anti-CD3 (145-2C11), CD4
(H129.19 and GK1.5), CD8 (53–67), CD19 (MB19-1 and 1D3),
CD25 (7D4), CD44 (IM7), B220 (CD45R) (RA3-6B2), TCRb
(H57-597), TCRc (UC7-13D5), c-Kit (ACK2 and 2B8), and
Sca1 (D7) antibodies (BD Pharmingen and eBiosacince).
Kendall’s coefficient of concordance, Wilcoxon matched pairs
test, and Student’s t-test were used in the statistical evaluation.
For cell-cycle analysis, lymphoid cells were fixed in 70% ethanol,
stained with propidium iodide and analyzed using FACS
Calibur (Becton-Dickinson) with CellQuest software. Annexin
V staining was performed as recommended by the manufacture
(Roche).
DNA and Expression Analyses
Comparative genomic hybridization (CGH) and Spectral
karyotyping (SKY) were performed at the Roswell Park Cancer
Institute following published procedures [40,41]. For SKY
analysis, metaphase chromosomes were prepared from tumor
cell lines at early-passage numbers. Ten to twenty metaphases
were analyzed for each tumor. To assay for recombinations
within and between TCRG and TCRB loci, nested PCR was
performed as described previously [26]. Deletions between
breakpoint regions at positions 4926 and 16674 of the mouse
Notch1 gene were examined as described [29]. To assay for
Bcl11b internal deletions, nested PCR was performed using
primers homologous to the major breakpoint regions within
introns 1 and 3 [28]. The identities of amplified PCR fragments
were confirmed by DNA sequencing. Semiquantitative and Real-
Time RT-PCR analyses were performed using whole cell RNAs
prepared from primary lymphoid cells or tumors and previously
described oligonucleotide primers. The sequences of primers are
listed in Table S1. Relative expression of the target genes was
calculated using the DCT method described previously: Relative
expression=2
2DCT,w h e r eDCT=CT (Target gene) - CT
(HPRT).
Figure 6. V(D)J recombination poses a risk for genomic instability in thymocytes deficient for p53 and p73. A, B. Genomyc PCR
analysis of internal deletion at the Bcl11b and Notch1 loci in thymocytes from WT, p532/2,p 7 3 2/2,a n dD K Om i c e( A), and in lymphomas
derived from p532/2,p 5 3 2/2p73+/2 and p532/2p732/2 mice (B). Consistent data were obtained from three mice of each genotype. TCRb
and TCRc gene rearrangements are shown for controls. Tumor numbers are indicated. C. Relative frequency of rearranged Bcl11b gene in
thymocytes from WT, p532/2,p 7 3 2/2, and DKO mice. The results are representative of six mice of each genotype. The error bars represent the
standard error.
doi:10.1371/journal.pone.0007784.g006
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Figure S1 A. Total cell numbers in thymi of ageing mice of the
indicated genotypes. The error bars represent the standard error
obtained from three experiments. B. Kaplan-Meier curves of
tumor-free survival of p53+/2 and p53+/2p732/2 mice. The
number of mice of each genotype is indicated. C. Tumor spectra
in mice of the indicated genotypes.
Found at: doi:10.1371/journal.pone.0007784.s001 (0.57 MB TIF)
Figure S2 Quantitative RT-PCR analysis of genes encoding
critical factors of T cell development in DN (A) or DP thymocytes
(B, C) of the indicated genotypes. Each sample was analyzed in
duplicate. mRNA expression levels were normalized to hypoxan-
thine-guanine phosphoribosyl transferase (HPRT) mRNA
amount.
Found at: doi:10.1371/journal.pone.0007784.s002 (0.06 MB
PDF)
Figure S3 CGH analysis of chromosomal alterations in primary
T cell lymphomas from p532/2, p53-p73+/2 and p532/
2p732/2 mice. The results are representative of five tumors of
each genotype. Chromosomal gains are shown in green, while
chromosomal losses are shown in red. The blue boxes indicate the
most common chromosomal aberrations.
Found at: doi:10.1371/journal.pone.0007784.s003 (1.25 MB TIF)
Figure S4 SKY analysis of cell lines established from p532/2,
p53-p73+/2 and p532/2p732/2 T cell lymphomas. Chromo-
somes with numerical changes (white circles) and translocations
(yellow circles) are indicated.
Found at: doi:10.1371/journal.pone.0007784.s004 (2.99 MB TIF)
Table S1 Primers for quantitative RT-PCR.
Found at: doi:10.1371/journal.pone.0007784.s005 (0.04 MB
DOC)
Acknowledgments
The authors would like to thank Ute M. Moll and Natalia Petrenko for
their support and careful reading of the manuscript.
Author Contributions
Conceived and designed the experiments: OP. Performed the experiments:
AN GP NN SiM OP. Analyzed the data: AN GP NN SiM OP.
Contributed reagents/materials/analysis tools: NN SiM OP. Wrote the
paper: OP.
References
1. Jost CA, Marin MC, Kaelin Jr. WG (1997) p73 is a simian [correction of
human] p53-related protein that can induce apoptosis. Nature 389: 191–194.
2. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, et al. (1997)
Monoallelically expressed gene related to p53 at 1p36, a region frequently
deleted in neuroblastoma and other human cancers. Cell 90: 809–819.
3. Senoo M, Manis JP, Alt FW, McKeon F (2004) p63 and p73 are not required for
the development and p53-dependent apoptosis of T cells. Cancer Cell 6: 85–89.
4. Talos F, Nemajerova A, Flores ER, Petrenko O, Moll UM (2007) p73
Suppresses Polyploidy and Aneuploidy in the Absence of Functional p53. Mol
Cell 27: 647–659.
5. Melino G, De Laurenzi V, Vousden KH (2002) p73: Friend or foe in
tumorigenesis. Nat Rev Cancer 2: 605–615.
6. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, et al. (1999)
Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and
Burkitt’s lymphoma is associated with 59 CpG island methylation. Cancer Res
59: 3352–3356.
7. Martinez-Delgado B, Melendez B, Cuadros M, Jose Garcia M, Nomdedeu J,
et al. (2002) Frequent inactivation of the p73 gene by abnormal methylation or
LOH in non-Hodgkin’s lymphomas. Int J Cancer 102: 15–19.
8. Gutierrez MI, Siraj AK, Bhargava M, Ozbek, Banavali S, et al. (2003)
Concurrent methylation of multiple genes in childhood ALL: Correlation with
phenotype and molecular subgroup. Leukemia 17: 1845–1850.
9. Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, et al. (2003) p73
Expression in human normal and tumor tissues: loss of p73alpha expression is
associated with tumor progression in bladder cancer. Clin Cancer Res 9:
5642–5651.
10. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, et al. (2004)
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian
cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res
64: 2449–2460.
11. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, et al. (2004)
Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer
Res 10: 626–633.
12. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, et al. (2008)
TAp73 knockout shows genomic instability with infertility and tumor suppressor
functions. Genes Dev 22: 2677–2691.
13. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, et al. (2000) p73-
deficient mice have neurological, pheromonal and inflammatory defects but lack
spontaneous tumours. Nature 404: 99–103.
14. Petrenko O, Zaika A, Moll UM (2003) deltaNp73 facilitates cell immortalization
and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell
Biol 23: 5540–5555.
15. Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nat Rev
Cancer 7: 165–168.
16. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, et al. (2005) Tumor
predisposition in mice mutant for p63 and p73: evidence for broader tumor
suppressor functions for the p53 family. Cancer Cell 7: 363–373.
17. Perez-Losada J, Wu D, DelRosario R, Balmain A, Mao JH (2005) p63 and p73
do not contribute to p53-mediated lymphoma suppressor activity in vivo.
Oncogene 24: 5521–5524.
18. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, et al. (2002) p63 and p73
are required for p53-dependent apoptosis in response to DNA damage. Nature
416: 560–564.
19. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr. CA, et al.
(1992) Mice deficient for p53 are developmentally normal but susceptible to
spontaneous tumours. Nature 356: 215–221.
20. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, et al. (1994)
Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7.
21. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery Jr. CA, et al.
(1995) Effects of genetic background on tumorigenesis in p53-deficient mice.
Mol Carcinog 14: 16–22.
22. Attardi LD, Donehower LA (2005) Probing p53 biological functions through the
use of genetically engineered mouse models. Mutat Res 576: 4–21.
23. Blackburn CC, Manley NR (2004) Developing a new paradigm for thymus
organogenesis. Nat Rev Immunol 4: 278–289.
24. Bassing CH, Swat W, Alt FW (2002) The mechanism and regulation of
chromosomal V(D)J recombination. Cell 109 Suppl: S45–55.
25. Pals ST, de Gorter DJ, Spaargaren M (2007) Lymphoma dissemination: the
other face of lymphocyte homing. Blood 110: 3102–3111.
26. Lista F, Bertness V, Guidos CJ, Danska JS, Kirsch IR (1997) The absolute
number of trans-rearrangements between the TCRG and TCRB loci is
predictive of lymphoma risk: a severe combined immune deficiency (SCID)
murine model. Cancer Res 57: 4408–4413.
27. Kang J, Bronson RT, Xu Y (2002) Targeted disruption of NBS1 reveals its roles
in mouse development and DNA repair. Embo J 21: 1447–1455.
28. Sakata J, Inoue J, Ohi H, Kosugi-Okano H, Mishima Y, et al. (2004)
Involvement of V(D)J recombinase in the generation of intragenic deletions in
the Rit1/Bcl11b tumor suppressor gene in gamma-ray-induced thymic
lymphomas and in normal thymus of the mouse. Carcinogenesis 25: 1069–1075.
29. Tsuji H, Ishii-Ohba H, Katsube T, Ukai H, Aizawa S, et al. (2004) Involvement
of illegitimate V(D)J recombination or microhomology-mediated nonhomolo-
gous end-joining in the formation of intragenic deletions of the Notch1 gene in
mouse thymic lymphomas. Cancer Res 64: 8882–8890.
30. Ohi H, Mishima Y, Kamimura K, Maruyama M, Sasai K, et al. (2007) Multi-
step lymphomagenesis deduced from DNA changes in thymic lymphomas and
atrophic thymuses at various times after gamma-irradiation. Oncogene 26:
5280–5289.
31. Bogue MA, Zhu C, Aguilar-Cordova E, Donehower LA, Roth DB (1996) p53 is
required for both radiation-induced differentiation and rescue of V(D)J
rearrangement in scid mouse thymocytes. Genes Dev 10: 553–565.
32. Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MT, et al. (1996) V(D)J
recombination activates a p53-dependent DNA damage checkpoint in scid
lymphocyte precursors. Genes Dev 10: 2038–2054.
33. Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, et al. (1996) Mutations
in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 10:
2055–2066.
34. Haks MC, Krimpenfort P, van den Brakel JH, Kruisbeek AM (1999) Pre-TCR
signaling and inactivation of p53 induces crucial cell survival pathways in pre-T
cells. Immunity 11: 91–101.
35. Murga C, Barber DF (2002) Molecular mechanisms of pre-T cell receptor-
induced survival. J Biol Chem 277: 39156–39162.
Role of p73 in Lymphomagenesis
PLoS ONE | www.plosone.org 9 November 2009 | Volume 4 | Issue 11 | e778436. Haines BB, Ryu CJ, Chang S, Protopopov A, Luch A, et al. (2006) Block of T
cell development in P53-deficient mice accelerates development of lymphomas
with characteristic RAG-dependent cytogenetic alterations. Cancer Cell 9:
109–120.
37. Tsuji H, Ishii-Ohba H, Noda Y, Kubo E, Furuse T, et al. (2009) Rag-dependent
and Rag-independent mechanisms of Notch1 rearrangement in thymic
lymphomas of Atm(2/2) and scid mice. Mutat Res 660: 22–32.
38. Osborne BA, Minter LM (2007) Notch signalling during peripheral T-cell
activation and differentiation. Nat Rev Immunol 7: 64–75.
39. Wakabayashi Y, Watanabe H, Inoue J, Takeda N, Sakata J, et al. (2003) Bcl11b
is required for differentiation and survival of alphabeta T lymphocytes. Nat
Immunol 4: 533–539.
40. Cowell JK, Matsui S, Wang YD, LaDuca J, Conroy J, et al. (2004) Application
of bacterial artificial chromosome array-based comparative genomic hybridiza-
tion and spectral karyotyping to the analysis of glioblastoma multiforme. Cancer
Genet Cytogenet 151: 36–51.
41. Nowak NJ, Miecznikowski J, Moore SR, Gaile D, Bobadilla D, et al. (2007)
Challenges in array comparative genomic hybridization for the analysis of
cancer samples. Genet Med 9: 585–95.
Role of p73 in Lymphomagenesis
PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7784